Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Ganciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.91 |
| ▸ | VCP | P55072 | 1/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.91 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | PNP | P00491 | 6/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | EDNRA | P25101 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL1061493 | 1.00 | BLM (0.91) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL6047042 | 1.00 | BLM (0.91) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL3033 | 0.95 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL2160505 | 0.95 | BLM (1.00) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL603705 | 0.95 | BLM (0.85) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL25915 | 0.94 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL11093368 | 0.94 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL1242615 | 0.94 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10481442 | 0.94 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL10481436 | 0.94 | BLM (0.98) | BLMMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336901-A1 | Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta | UNIV TEMPLE (US) | 2024-10-10 | — | — | US | claimed |
| US-11993791-B2 | Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-28 | — | — | US | claimed |
| EP-3368692-B1 | MODIFICATION OF 3' TERMINAL ENDS OF NUCLEIC ACIDS BY DNA POLYMERASE THETA | UNIV TEMPLE (US) | 2021-07-21 | — | — | EP | claimed |
| US-20210171920-A1 | Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta | UNIV TEMPLE (US) | 2021-06-10 | — | — | US | claimed |
| US-10865396-B2 | Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-12-15 | — | — | US | claimed |
| US-20180312820-A1 | Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-11-01 | — | — | US | claimed |
| EP-3368692-A1 | MODIFICATION OF 3' TERMINAL ENDS OF NUCLEIC ACIDS BY DNA POLYMERASE THETA | Temple University Of The Commonwealth System Of Higher Education (US) | 2018-09-05 | — | — | EP | claimed |
| EP-2914721-B1 | A RNA TRANS-SPLICING MOLECULE (RTM) FOR USE IN THE TREATMENT OF CANCER | BAUER JOHANN (AT) | 2017-09-13 | — | — | EP | claimed |
| WO-2017075421-A1 | MODIFICATION OF 3' TERMINAL ENDS OF NUCLEIC ACIDS BY DNA POLYMERASE THETA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-05-04 | — | — | WO | claimed |
| US-20150250901-A1 | RNA TRANS-SPLICING MOLECULE (RTM) FOR USE IN THE TREATMENT OF CANCER | BAUER JOHANN (AT) | 2015-09-10 | — | — | US | claimed |
| EP-2914721-A1 | A RNA TRANS-SPLICING MOLECULE (RTM) FOR USE IN THE TREATMENT OF CANCER | Bauer, Johann (AT) | 2015-09-09 | — | — | EP | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| WO-2014068063-A1 | A RNA TRANS-SPLICING MOLECULE (RTM) FOR USE IN THE TREATMENT OF CANCER | BAUER JOHANN (AT) | 2014-05-08 | — | — | WO | claimed |
| WO-2026102462-A1 | ENGINEERED CELLS FOR TREATING DIABETES | CITY OF HOPE (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12576135-B2 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | CHIMERA BIOENGINEERING, INC. | 2026-03-17 | — | — | US | disclosed |
| US-12527821-B2 | Compositions and methods related to tumor cell killers and vaccines | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-1997029196-A1 | VARIANTS OF THYMIDINE KINASE, RELATED NUCLEIC ACIDS SEQUENCES AND THEIR USE IN GENIC THERAPY | RHONE-POULENC RORER S.A. (FR) | 1997-08-14 | — | — | WO | disclosed |
| WO-1995029704-A1 | CELL LINES OBTAINED BY IN VIVO MIGRATION AND BY FUSION WITH AUTOIMMUNE CELLS | FREEMAN SCOTT (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0118393-A2 | Methods and compositions for expression of competent eukaryotic gene products | BATTELLE MEMORIAL INSTITUTE (CH) | 1984-09-12 | — | — | EP | disclosed |
| US-4464359-A | VIRICIDES | RESEARCH CORPORATION (US) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576135-B2 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | BRCA1, RNASE1, NSUN2 | BLM 2408/4885MEN1 579/4885ALDH1A1 3189/4885 |
| US-12527821-B2 | Compositions and methods related to tumor cell killers and vaccines | PBK, IFNG, IL2 | BLM 1771/4885MEN1 1475/4885ALDH1A1 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.